Date: 2016-03-29
Type of information: Commercialisation agreement
Compound: SelectMDx™ for Prostate Cancer test
Company: MDxHealth (Belgium) Andros Men's Health Clinic (The Netherlands)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: commercialisation
Action mechanism: biomarker/diagnostic test. The novel biomarkers that make up SelectMDx were discovered by Prof. Dr. Jack Schalken, original developer of the PCA3 assay, and his team at the Department of Urology at Radboud University Medical Center in the Netherlands. This non-invasive urine based test is used to identify men at risk for aggressive prostate cancer who may benefit from early detection and an initial prostate biopsy or magnetic resonance imaging (MRI). A negative SelectMDx also helps identify men at very low risk for clinically significant cancer, and could reduce unnecessary invasive biopsies, thereby reducing healthcare costs.
Disease: prostate cancer
Details: * On March 29, 2016, MDxHealth announced that it has partnered with Andros Men's Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx™ for Prostate Cancer test to their patients. Through this new partnership, Andros Men's Clinic (Mannenkliniek), the largest independent urological treatment center in The Netherlands, has added SelectMDx to its panel of men's prostate cancer diagnostic tests. Under this partnership the Andros Men's Health Clinic will offer the SelectMDx test to all patients considered at risk for prostate cancer and over 500 patients to undergo testing in the first year alone. The SelectMDx test will be available to Andros Men's Health Clinic patients starting on April 1st 2016.
Financial terms:
Latest news:
